Vistagen Therapeutics, Inc (VTGN) insider trading
Every open-market stock purchase and sale by Vistagen Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- No open-market insider trades in the last 12 months.
- Last insider buy: Commodore Capital LP (10% owner), $18M, 3 years ago.
Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales). Last close $0.24 on Jul 31, 2026.
Recent VTGN insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jul 29, 2026 | Douglas J Williamson (Insider) | Bought (not open market) | — |
| May 18, 2026 | Angel S Angelov (C-suite exec) | Bought (not open market) | $89.3K |
| Apr 7, 2026 | Nick B. Tressler (CFO) | Bought (not open market) | — |
| Apr 7, 2026 | Reid G. Adler (C-suite exec) | Bought (not open market) | — |
| Apr 7, 2026 | Shawn Singh (CEO) | Bought (not open market) | — |
| Apr 7, 2026 | Joshua S. Prince (COO) | Bought (not open market) | — |
| Apr 7, 2026 | Elissa S. Cote (Officer) | Bought (not open market) | — |
| Apr 7, 2026 | Reid G. Adler (C-suite exec) | Bought (not open market) | — |
| Apr 7, 2026 | Shawn Singh (CEO) | Bought (not open market) | — |
| Apr 7, 2026 | Joshua S. Prince (COO) | Bought (not open market) | — |
| Dec 31, 2025 | Joshua S. Prince (COO) | Bought (not open market) | $2.5K |
| Dec 1, 2025 | Nick B. Tressler (CFO) | Bought (not open market) | $665K |
| Oct 27, 2025 | Paul R Edick (Insider) | Bought (not open market) | $137K |
Who's trading VTGN
- Douglas J Williamson, Insider: other filings, last Jul 29, 2026
- Angel S Angelov, C-suite exec: other filings, last May 18, 2026
- Reid G. Adler, C-suite exec: other filings, last Apr 7, 2026
- Elissa S. Cote, Officer: other filings, last Apr 7, 2026
- Joshua S. Prince, COO: other filings, last Apr 7, 2026
- Shawn Singh, CEO: other filings, last Apr 7, 2026
- Nick B. Tressler, CFO: other filings, last Apr 7, 2026
- Paul R Edick, Insider: other filings, last Oct 27, 2025
Get free alerts when an insider at Vistagen Therapeutics, Inc files a new trade →